Combination of oral methotrexate and oral mini‐pulse dexamethasone vs either agent alone in vitiligo treatment with follow up by dermoscope

ElGhareeb, Mohamed Ibrahim; Metwalli, Mohamed; AbdelMoneim, Nehal

doi:10.1111/dth.13586

Cited by 12 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All groups received the treatment for 3 months. The results demonstrated a significant decrease in disease extension in group C compared with the other groups (93). The side effects of MTX are hepatotoxicity, idiosyncratic pulmonary toxicity, pancytopenia, nausea, vomiting and diarrhea (24).…”

Section: Systemic Treatmentmentioning

confidence: 91%

“…New lesions developed during treatment in 23% of patients in the MTX group and 28% of patients in the corticosteroid group (92). ElGhareeb et al (93) performed a study with 42 patients to assess the efficacy and safety of oral MTX and oral mini pulse of dexamethasone, used either alone or in combination. Patients were randomly divided into three groups.…”

Section: Systemic Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Updates and new medical treatments for vitiligo (Review)

et al. 2021

View full text Add to dashboard Cite

Vitiligo is a multifactorial disease characterized by the loss of skin pigment, which results in achromic macules and patches. There are currently several medical treatments available, which aim to arrest progression and induce skin repigmentation. These treatments alone or combined have exhibited varying degrees of pigmentation, and the majority are safe and effective. All therapies for vitiligo are limited, and no known treatment can consistently produce repigmentation in all patients. Individualized treatment is appropriate according to the location, clinical presentation and the presence of disease activity. The present review summarizes the medical treatments available for vitiligo: Systemic and topic pharmacological therapies, physical and depigmentation treatments. Several treatments are still underway and have not yet been approved. However, due to the promising preliminary results, these are also mentioned in the present review. Contents 1. Introduction 2. Pharmacological treatment 3. Physical therapy 4. Depigmentation therapies 5. Conclusions

show abstract

Section: Systemic Treatmentmentioning

confidence: 91%

Section: Systemic Treatmentmentioning

confidence: 99%

Updates and new medical treatments for vitiligo (Review)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Additionally, dermoscopy has been reported to be a reliable tool to assess initial therapeutic response to treatments as it may show increases in perilesional and intralesional pigmentation that are not visible to the naked eye [44,45].…”

Section: Pigmentary Dermatosesmentioning

confidence: 99%

Dermoscopy in Monitoring and Predicting Therapeutic Response in General Dermatology (Non-Tumoral Dermatoses): An Up-To-Date Overview

Errichetti

2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Besides the well-known use in supporting the non-invasive diagnosis of non-tumoral dermatoses (general dermatology), dermoscopy has been shown to be a promising tool also in predicting and monitoring therapeutic outcomes of such conditions, with the consequent improvement/optimization of their treatment. In the present paper, we sought to provide an up-to-date overview on the use of dermoscopy in highlighting response predictor factors and evaluating therapeutic results in the field of general dermatology according to the current literature data. Several dermatoses may somehow benefit from such applications, including inflammatory conditions (psoriasis, lichen planus, dermatitis, granulomatous conditions, erythro-telangiectatic rosacea, Zoon balanitis and vulvitis, cutaneous mastocytosis, morphea and extra-genital lichen sclerosus), pigmentary disorders (vitiligo and melasma) and infectious dermatoses (scabies, pediculosis, demodicosis and viral warts).

show abstract

“…Repigmentation is always the first purpose of treatment, and the next step is to stabilize the disease, stop melanocyte dysfunction, and provide psychological care and good quality of life, especially for patients with skin of color. 14,15 Treating this disease remains one of the most difficult therapeutic challenges among dermatologists; however, there are many treatment options, such as medications, phototherapy, and surgical grafts. 16 Interleukin-15 (IL-15) is a potent cytokine in the pathogenesis of immune-mediated diseases, especially those associated with CD8+ T-cell malfunction, such as psoriasis, alopecia areata, inflammatory bowel disease, and vitiligo.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of using oral methotrexate with phototherapy in the treatment of vitiligo in comparison with single phototherapy treatment: A double‐blinded randomized controlled trial

Lajevardi,

Hosseini,

Heidari

2023

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

BackgroundVitiligo is an acquired skin disease with a worldwide prevalence of 0.5%–2% and a tendency to involve both genders. Although the exact pathologic mechanism is unknown, there is some evidence for the role of autoimmunity in this disease. Based on this theory, various immunosuppressive agents, such as topical or systemic corticosteroids and phototherapy (including narrowband ultraviolet B), are used. Methotrexate is another immunosuppressant that has recently become popular as a single treatment for vitiligo; however, the synergistic effect and its superiority over other treatments are two crucial factors that are still obscure. This study aimed to compare the efficacy of methotrexate+ NB‐UVB versus placebo+ NB‐UVB in vitiligo patients.MethodsIn this double‐blinded, randomized controlled trial, 42 patients were randomly allocated into two groups: the first group received three times weekly NB‐UVB plus placebo, and the second group was treated with three times weekly NB‐UVB in combination with a weekly dose of 12.5 mg MTX. The total duration of treatment was 6 months, patients were followed up every 2 months, and the assessment tools were VASI (repigmentation indicator) and VIDA (disease activity indicator) scores.ResultsBoth treatment groups showed improvement in VASI and VIDA scores during 6‐month follow‐up, but no statistical significance was found between the two treatment methods.ConclusionThis study demonstrated that both treatment modalities were equally effective, and further studies are required to evaluate the efficacy of MTX with other medications with longer follow‐up and a larger sample size.

show abstract

Combination of oral methotrexate and oral mini‐pulse dexamethasone vs either agent alone in vitiligo treatment with follow up by dermoscope

Cited by 12 publications

References 10 publications

Updates and new medical treatments for vitiligo (Review)

Updates and new medical treatments for vitiligo (Review)

Dermoscopy in Monitoring and Predicting Therapeutic Response in General Dermatology (Non-Tumoral Dermatoses): An Up-To-Date Overview

Efficacy of using oral methotrexate with phototherapy in the treatment of vitiligo in comparison with single phototherapy treatment: A double‐blinded randomized controlled trial

Contact Info

Product

Resources

About